Korro Bio, Inc. (KRRO)
(Real Time Quote from BATS)
$48.95 USD
-0.20 (-0.41%)
Updated Jul 15, 2024 03:22 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KRRO 48.95 -0.20(-0.41%)
Will KRRO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KRRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRRO
Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade
Best Momentum Stocks to Buy for February 16th
KRRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for February 16th
Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect?
Other News for KRRO
KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023
Korro Bio’s Chief Scientific Officer Announces Resignation
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), AbbVie (ABBV) and Emergent Biosolutions (EBS)
option delistings on June 3rd
Korro to Participate in Upcoming June Investor and Scientific Conferences